Stock Analiz

Gain Therapeutics, Inc. GANX

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.04Market cap $46M
Open the interactive analysis →

Gain Therapeutics, Inc. (GANX) is a healthcare company listed in the US with a market value of about $46M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -101%.

About Gain Therapeutics

Gain Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $28881 in 2020 to $55180 in 2023, growth of about 24.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 177% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B4.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-20442.8%
ROIC (5-yr avg.)-101.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue——$55180$140108$164994$28881
Net income-$20M-$20M-$22M-$18M-$14M-$4M
Free cash flow—-$19M-$19M-$15M-$12M-$3M
EPS (diluted)$-0.61$-0.89$-1.71$-1.48$-1.37$-1.33
Net margin——-40354.3%-12555.1%-8418.9%-12387.7%
ROIC-76.6%-201.1%-129.2%-69.7%-30.0%-36.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Gain Therapeutics pay a dividend?

Not currently.

Is Gain Therapeutics a good stock to buy?

We do not give buy or sell advice. Gain Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.